Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children
Launched by IPSEN · Jul 14, 2006
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • male
- • acute watery diarrhoea defined as at least 3 watery stools per 24 hours
- • duration of watery diarrhoea of less than 72 hours and with at least one watery stool during the last 12 hours
- • dehydration signs requiring oral rehydration according to current WHO guidelines
- Exclusion Criteria:
- • severe dehydration that needs IV therapy
- • presence of gross blood in stools
- • fever \> 39 degrees Celsius
- • current treatment by an antidiarrheal medication
About Ipsen
Ipsen is a global biopharmaceutical group dedicated to innovation and specialty care, focusing on the discovery, development, and commercialization of transformative medicines for patients with serious diseases. With a strong emphasis on oncology, neuroscience, and rare diseases, Ipsen leverages cutting-edge research and advanced technologies to deliver high-quality therapies that address unmet medical needs. Committed to scientific excellence and ethical practices, Ipsen collaborates with healthcare professionals and stakeholders to drive patient-centered solutions and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Breña, , Peru
Cercado, , Peru
Huacho, , Peru
Ica, , Peru
La Molina, , Peru
Lima, , Peru
Lima, , Peru
Lima, , Peru
Lima, , Peru
Lima, , Peru
San Borga, , Peru
San Miguel, , Peru
Zárate, , Peru
Patients applied
Trial Officials
Ipsen Medical Director
Study Director
Ipsen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials